Pharmacokinetics of Micafungin in Adult Patients with Invasive Candidiasis and Candidaemia.

E. KUSE 1, I. DEMEYER 2, P. STEVENSON 3, N. UNDRE3;

Author address: 

1Medizinische Hochschule Hannover, Hannover, Germany, 2Onse Lieve Vrouw Ziekenhaus, Aalst, Belgium, 3Astellas Pharma GmbH, Munich, Germany.

Abstract: 

Background: Pharmacokinetics (PK) of micafungin in patients with confirmed invasive candiasis (IC) or candidaemia (C) have previously not been characterised. We report here the PK of micafungin elucidated in this patient population. Methods: Patients (n=20) received micafungin (100 mg daily for a minimum of 14 days). Plasma concentration-time profiles to determine the PK were taken after the first dose (Day 1) and on the last day of treatment. Results: Mean age was 50 years (range of 18 to 84) and mean weight was 67 kg (48 to 103 kg). There were 13 Caucasians, 3 Thais, 1 Black, 1 Asian Indian, 1 Mulatto and 1 Cape Coloured. Key PK parameters are given below. Conclusions: This study has characterised the PK of micafungin in neutropenic and non-neutropenic patients with confirmed IC or C caused by Candida albicans and non-albicans Candida species. The mean half-life and the mean clearance remained largely unchanged after repeated daily dosing for 14 or 28 days. There was also no accumulation of micafungin between Day 1 and end of therapy beyond that expected for a drug with linear PK. Systemic exposure to metabolites was low throughout the study and therefore, metabolites of micafungin do not contribute to the therapeutic antifungal effectiveness of micafungin. In general, the PK parameters observed in this patient population were similar to those obtained in earlier studies in other adult patient populations
2007

abstract No: 

A-770

Full conference title: 

47th Interscience Conference on Antimicrobial agents and Chemotherapy
    • ICAAC 47th